Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions. Notable products developed or marketed by the company include immune checkpoint inhibitors and combination oncology regimens, anticoagulant therapies, and immunomodulatory agents. The company maintains a sizable R&D organization and invests in clinical development, translational science and collaborative research to expand indications for existing therapies and to advance novel modalities such as targeted agents and cell‑based approaches.
The modern Bristol Myers Squibb was formed through the 1989 merger of Bristol‑Myers and Squibb, and it expanded materially with the acquisition of Celgene in 2019, which significantly broadened its hematology and oncology franchise and added a substantial product and pipeline base. BMS has a history of pursuing strategic licensing agreements, partnerships and acquisitions to complement internal discovery efforts and to access new technologies and therapeutic candidates.
BMS operates globally, serving patients and healthcare systems across North America, Europe, Asia and other regions through direct commercial operations and partner networks. The company is led by a senior executive team responsible for corporate strategy, R&D and global operations; as of the most recent public disclosures the company’s chief executive officer is Giovanni Caforio. Bristol Myers Squibb continues to prioritize innovation, regulatory engagement and collaborations with academic and industry partners to address unmet medical needs.
AI Generated. May Contain Errors.
